New treatments/targets for primary biliary cholangitis.

Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure?

AST/platelet ratio index associates with progression to hepatic failure and correlates with histological fibrosis stage in Japanese patients with primary biliary cirrhosis

EASL Clinical Practice Guidelines: Management of cholestatic liver diseases

Complementary Stimulation of Hepatobiliary Transport and Detoxification Systems by Rifampicin and Ursodeoxycholic Acid in Humans

Nuclear Receptor Ligands: Rational and Effective Therapy for Chronic Cholestatic Liver Disease?

Efficacy and Safety of Ursodeoxycholic Acid Versus Cholestyramine in Intrahepatic Cholestasis of Pregnancy

24-norUrsodeoxycholic Acid Is Superior to Ursodeoxycholic Acid in the Treatment of Sclerosing Cholangitis in Mdr2 (Abcb4) Knockout Mice

ABC transporter regulation by bile acids: where PXR meets FXR

Prevalence and Predictors of Esophageal Varices in Patients With Primary Biliary Cirrhosis

Successful treatment of severe unconjugated hyperbilirubinemia via induction of UGT1A1 by rifampicin

From Bases to Basis: Linking Genetics to Causation in Primary Biliary Cirrhosis

A Predictive Model for Fatigue and Its Etiologic Associations in Primary Biliary Cirrhosis

Patients With Autoimmune Hepatitis Who Have Antimitochondrial Antibodies Need Long-term Follow-up to Detect Late Development of Primary Biliary Cirrhosis

Fetal microchimerism: an aetiological factor in primary biliary cirrhosis?

NKT-cell subsets: Promoters and protectors in inflammatory liver disease